O	0	9	Targeting	Target	VBG	B-VP
O	10	13	TNF	TNF	NN	B-NP
O	14	17	for	for	IN	B-PP
O	18	27	Treatment	Treatment	NN	B-NP
O	28	30	of	of	IN	B-PP
B-Cancer	31	37	Cancer	Cancer	NN	B-NP
O	38	41	and	and	CC	I-NP
O	42	54	Autoimmunity	Autoimmunity	NN	I-NP
O	54	55	.	.	.	O

O	56	61	Tumor	Tumor	NN	B-NP
O	62	70	necrosis	necrosis	NN	I-NP
O	71	77	factor	factor	NN	I-NP
O	77	78	-	-	HYPH	O
O	78	83	alpha	alpha	SYM	B-NP
O	84	85	(	(	(	O
O	85	88	TNF	TNF	NN	B-NP
O	88	89	-	-	HYPH	O
O	89	94	alpha	alpha	SYM	B-NP
O	94	95	)	)	)	O
O	96	99	was	be	VBD	B-VP
O	100	105	first	first	RB	I-VP
O	106	114	isolated	isolate	VBN	I-VP
O	115	118	two	two	CD	B-NP
O	119	126	decades	decade	NNS	I-NP
O	127	130	ago	ago	RB	B-ADVP
O	131	133	as	as	IN	B-PP
O	134	135	a	a	DT	B-NP
O	136	154	macrophageproduced	macrophageproduce	VBN	I-NP
O	155	162	protein	protein	NN	I-NP
O	163	167	that	that	WDT	B-NP
O	168	171	can	can	MD	B-VP
O	172	183	effectively	effectively	RB	I-VP
O	184	188	kill	kill	VB	I-VP
B-Cell	189	194	tumor	tumor	NN	B-NP
I-Cell	195	200	cells	cell	NNS	I-NP
O	200	201	.	.	.	O

O	202	205	TNF	TNF	NN	B-NP
O	205	206	-	-	HYPH	O
O	206	211	alpha	alpha	SYM	B-NP
O	212	214	is	be	VBZ	B-VP
O	215	219	also	also	RB	B-ADVP
O	220	222	an	an	DT	B-NP
O	223	232	essential	essential	JJ	I-NP
O	233	242	component	component	NN	I-NP
O	243	245	of	of	IN	B-PP
O	246	249	the	the	DT	B-NP
B-Anatomical_system	250	256	immune	immune	JJ	I-NP
I-Anatomical_system	257	263	system	system	NN	I-NP
O	264	267	and	and	CC	O
O	268	270	is	be	VBZ	B-VP
O	271	279	required	require	VBN	I-VP
O	280	283	for	for	IN	B-PP
O	284	297	hematopoiesis	hematopoiesis	NN	B-NP
O	297	298	,	,	,	O
O	299	302	for	for	IN	B-PP
O	303	313	protection	protection	NN	B-NP
O	314	318	from	from	IN	B-PP
O	319	328	bacterial	bacterial	JJ	B-NP
O	329	338	infection	infection	NN	I-NP
O	339	342	and	and	CC	B-PP
O	343	346	for	for	IN	B-PP
B-Cell	347	353	immune	immune	JJ	B-NP
I-Cell	354	358	cell	cell	NN	I-NP
O	358	359	-	-	HYPH	B-NP
O	359	367	mediated	mediate	VBN	I-NP
O	368	380	cytotoxicity	cytotoxicity	NN	I-NP
O	380	381	.	.	.	O

O	382	391	Extensive	Extensive	JJ	B-NP
O	392	400	research	research	NN	I-NP
O	400	401	,	,	,	O
O	402	409	however	however	RB	B-ADVP
O	409	410	,	,	,	O
O	411	414	has	have	VBZ	B-VP
O	415	423	revealed	reveal	VBN	I-VP
O	424	428	that	that	IN	B-SBAR
O	429	432	TNF	TNF	NN	B-NP
O	432	433	-	-	HYPH	O
O	433	438	alpha	alpha	SYM	B-NP
O	439	441	is	be	VBZ	B-VP
O	442	445	one	one	CD	B-NP
O	446	448	of	of	IN	B-PP
O	449	452	the	the	DT	B-NP
O	453	458	major	major	JJ	I-NP
O	459	466	players	player	NNS	I-NP
O	467	469	in	in	IN	B-PP
B-Cancer	470	475	tumor	tumor	NN	B-NP
O	476	486	initiation	initiation	NN	I-NP
O	486	487	,	,	,	O
O	488	501	proliferation	proliferation	NN	B-NP
O	501	502	,	,	,	O
O	503	511	invasion	invasion	NN	B-NP
O	511	512	,	,	,	O
O	513	525	angiogenesis	angiogenesis	NN	B-NP
O	526	529	and	and	CC	I-NP
O	530	540	metastasis	metastasis	NN	I-NP
O	540	541	.	.	.	O

O	542	545	The	The	DT	B-NP
O	546	561	proinflammatory	proinflammatory	JJ	I-NP
O	562	572	activities	activity	NNS	I-NP
O	573	577	link	link	VBP	B-VP
O	578	581	TNF	TNF	NN	B-NP
O	581	582	-	-	HYPH	O
O	582	587	alpha	alpha	SYM	B-NP
O	588	592	with	with	IN	B-PP
O	593	594	a	a	DT	B-NP
O	595	599	wide	wide	JJ	I-NP
O	600	607	variety	variety	NN	I-NP
O	608	610	of	of	IN	B-PP
O	611	621	autoimmune	autoimmune	JJ	B-NP
O	622	630	diseases	disease	NNS	I-NP
O	630	631	,	,	,	O
O	632	641	including	include	VBG	B-PP
O	642	651	psoriasis	psoriasis	NN	B-NP
O	651	652	,	,	,	O
O	653	665	inflammatory	inflammatory	JJ	B-NP
B-Organ	666	671	bowel	bowel	NN	I-NP
O	672	679	disease	disease	NN	I-NP
O	679	680	,	,	,	O
O	681	691	rheumatoid	rheumatoid	JJ	B-NP
O	692	701	arthritis	arthritis	NN	I-NP
O	701	702	,	,	,	O
O	703	711	systemic	systemic	JJ	B-NP
O	712	721	sclerosis	sclerosis	NN	I-NP
O	721	722	,	,	,	O
O	723	731	systemic	systemic	JJ	B-NP
O	732	737	lupus	lupus	NN	I-NP
O	738	751	erythematosus	erythematosus	NN	I-NP
O	751	752	,	,	,	O
O	753	761	multiple	multiple	JJ	B-NP
O	762	771	sclerosis	sclerosis	NN	I-NP
O	771	772	,	,	,	O
O	773	781	diabetes	diabetes	NN	B-NP
O	782	785	and	and	CC	O
O	786	796	ankylosing	ankylose	VBG	B-VP
O	797	808	spondylitis	spondylitis	NN	B-NP
O	808	809	.	.	.	O

O	810	818	Systemic	Systemic	JJ	B-NP
O	819	829	inhibitors	inhibitor	NNS	I-NP
O	830	832	of	of	IN	B-PP
O	833	836	TNF	TNF	NN	B-NP
O	837	841	such	such	JJ	B-PP
O	842	844	as	as	IN	I-PP
O	845	855	etanercept	etanercept	NN	B-NP
O	856	857	(	(	(	O
O	857	863	Enbrel	Enbrel	NN	B-NP
O	863	864	)	)	)	O
O	865	866	(	(	(	O
O	866	867	a	a	DT	B-NP
O	868	875	soluble	soluble	JJ	I-NP
O	876	879	TNF	TNF	NN	I-NP
O	880	888	receptor	receptor	NN	I-NP
O	888	889	)	)	)	O
O	890	893	and	and	CC	O
O	894	904	infliximab	infliximab	NN	B-NP
O	905	906	(	(	(	O
O	906	914	Remicade	Remicade	NN	B-NP
O	914	915	)	)	)	O
O	916	919	and	and	CC	O
O	920	930	adalimumab	adalimumab	NN	B-NP
O	931	932	(	(	(	O
O	932	938	Humira	Humira	NN	B-NP
O	938	939	)	)	)	O
O	940	941	(	(	(	O
O	941	945	anti	anti	AFX	O
O	945	946	-	-	HYPH	O
O	946	949	TNF	TNF	NN	B-NP
O	950	960	antibodies	antibody	NNS	I-NP
O	960	961	)	)	)	O
O	962	966	have	have	VBP	B-VP
O	967	971	been	be	VBN	I-VP
O	972	980	approved	approve	VBN	I-VP
O	981	984	for	for	IN	B-PP
O	985	988	the	the	DT	B-NP
O	989	998	treatment	treatment	NN	I-NP
O	999	1011	inflammatory	inflammatory	JJ	I-NP
B-Organ	1012	1017	bowel	bowel	NN	I-NP
O	1018	1025	disease	disease	NN	I-NP
O	1025	1026	,	,	,	O
O	1027	1036	psoriasis	psoriasis	NN	B-NP
O	1037	1040	and	and	CC	O
O	1041	1051	rheumatoid	rheumatoid	JJ	B-NP
O	1052	1061	arthritis	arthritis	NN	I-NP
O	1061	1062	.	.	.	O

O	1063	1068	These	These	DT	B-NP
O	1069	1074	drugs	drug	NNS	I-NP
O	1074	1075	,	,	,	O
O	1076	1083	however	however	RB	B-ADVP
O	1083	1084	,	,	,	O
O	1085	1092	exhibit	exhibit	VBP	B-VP
O	1093	1099	severe	severe	JJ	B-NP
O	1100	1104	side	side	NN	I-NP
O	1105	1112	effects	effect	NNS	I-NP
O	1113	1116	and	and	CC	O
O	1117	1120	are	be	VBP	B-VP
O	1121	1130	expensive	expensive	JJ	B-ADJP
O	1130	1131	.	.	.	O

O	1132	1137	Hence	Hence	RB	B-NP
B-Organism_subdivision	1138	1144	orally	orally	RB	I-NP
O	1145	1151	active	active	JJ	I-NP
O	1152	1160	blockers	blocker	NNS	I-NP
O	1161	1163	of	of	IN	B-PP
O	1164	1167	TNF	TNF	NN	B-NP
O	1167	1168	-	-	HYPH	O
O	1168	1173	alpha	alpha	SYM	B-NP
O	1174	1178	that	that	WDT	B-NP
O	1179	1182	are	be	VBP	B-VP
O	1183	1187	safe	safe	JJ	B-NP
O	1187	1188	,	,	,	I-NP
O	1189	1200	efficacious	efficacious	JJ	I-NP
O	1201	1204	and	and	CC	I-NP
O	1205	1216	inexpensive	inexpensive	JJ	I-NP
O	1217	1220	are	be	VBP	B-VP
O	1221	1229	urgently	urgently	RB	I-VP
O	1230	1236	needed	need	VBN	I-VP
O	1236	1237	.	.	.	O

O	1238	1246	Numerous	Numerous	JJ	B-NP
O	1247	1255	products	product	NNS	I-NP
O	1256	1260	from	from	IN	B-PP
B-Organism_subdivision	1261	1267	fruits	fruit	NNS	B-NP
O	1267	1268	,	,	,	O
B-Organism_subdivision	1269	1278	vegetable	vegetable	JJ	B-NP
O	1279	1282	and	and	CC	I-NP
O	1283	1294	traditional	traditional	JJ	I-NP
O	1295	1304	medicinal	medicinal	JJ	I-NP
O	1305	1311	plants	plant	NNS	I-NP
O	1312	1316	have	have	VBP	B-VP
O	1317	1321	been	be	VBN	I-VP
O	1322	1331	described	describe	VBN	I-VP
O	1332	1337	which	which	WDT	B-NP
O	1338	1341	can	can	MD	B-VP
O	1342	1350	suppress	suppress	VB	I-VP
O	1351	1354	TNF	TNF	NN	B-NP
O	1355	1365	expression	expression	NN	B-NP
O	1366	1369	and	and	CC	O
O	1370	1373	TNF	TNF	NN	B-NP
O	1374	1383	signaling	signaling	NN	I-NP
O	1384	1387	but	but	CC	O
O	1388	1393	their	their	PRP$	B-NP
O	1394	1402	clinical	clinical	JJ	I-NP
O	1403	1412	potential	potential	NN	I-NP
O	1413	1415	is	be	VBZ	B-VP
O	1416	1419	yet	yet	RB	B-ADJP
O	1420	1429	uncertain	uncertain	JJ	I-ADJP
O	1429	1430	.	.	.	O

